Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
Imbruvica seemed invincible in the marketplace. But a new book, “For Blood and Money,” shows how the drug’s creators left a trap door that led to its undoing. → Read More
In an exclusive excerpt from For Blood And Money, the untold story of Wayne Rothbaum and the worst trade of his life. But what cost him some $700 million turned out to be the boon for countless cancer patients. → Read More
From a $1 billion loan to Sam Bankman-Fried to missing funds and payment-disbursement emojis, here are some of the eye-popping revelations from FTX’s new CEO → Read More
‘2023 will likely be the year of a very significant global recession’: Greg Jensen has positioned the world's biggest hedge fund for more market mayhem ahead. He lands on the MarketWatch 50. → Read More
We are seeking nominations for the MarketWatch 50, the most influential people in markets in 2022. → Read More
The indictment of Bill Hwang reveals the mechanics of an operation that drove the trading of certain tech stocks just as today’s Nasdaq plummets → Read More
Covid’s Forgotten Hero: The Untold Story Of The Scientist Whose Breakthrough Made The Vaccines Possible → Read More
To buy one company each week, Joe Liemandt has ordered managers of his 2,500 remote workers to design work units—specialized tasks that workers can perform over and over, as if they were on an old-fashioned auto factory assembly line. → Read More
Started by four Hoosiers, JJMT Capital was the primary investment vehicle for Zachary Horwitz's alleged investment fraud. The original connection was when they were all together at IU. → Read More
Kicked out of Hong Kong and the hedge fund game, Bill Hwang plowed his $500 million net worth into a concentrated portfolio of U.S. internet stocks, like Netflix and Amazon, while shorting Under Armour, to become a trading force. → Read More
Last year, while the U. S. stock market returned 18% during a volatile pandemic bull market, Icahn’s hedge fund plunged by 14%. → Read More
Pascal Soriot's stunning corporate turnaround story at AstraZeneca is now mired in vaccine politics and doubt. → Read More
Delivering a game-changing vaccine was a sprint. Bourla says delivering returns for Pfizer shareholders is a marathon. → Read More
A preprint of preclinical data for Moderna’s coronavirus vaccine suggests it uses delivery technology that is covered by a patent owned by Arbutus and upheld last week. → Read More
For 24 years, this former banker quietly purchased small slices of the most expensive and top-selling drugs in the nation and became a billionaire. → Read More
Pfizer's COVID moonshot. Inside an effort that could change the world. → Read More
Cadre joins a growing list of high-profile technology companies like Airbnb and Uber that have laid off a large number of employees amid the pandemic → Read More
The blood cancer drug has been given to a small number of sick U.S. patients and massive clinical trials are being launched to determine its efficacy, as well as that of Imbruvica. → Read More
One of Pierre Andurand's hedge funds was up 122% in the first quarter; Boaz Weinstein's fund was up 72%. Ray Dalio's fund was down 16% in March; Robert Gibbins' was down 20%. → Read More
Investors are rushing into money market funds and corporations have tapped their credit lines. → Read More